Home > Renal cell carcinoma

Highlights

FDA okays axitinib for advanced kidney cancer

Tuesday, 31 January 2012- The US Food and Drug Administration today approved Inlyta (axitinib) to treat patients with advanced kidney cancer (renal cell carcinoma) who have not responded to another drug for this type of...

Edited by: JV

Elevated blood lead levels in smokers linked to higher kidney cancer risk

Wednesday, 25 January 2012- Higher than normal levels of lead in the blood may signal a risk two times higher than average of developing renal cell carcinoma in smokers, according to medical researchers.

"Past studies (in...

Edited by: JV

Radiofrequency ablation (RFA) therapy for renal angiomyolipoma

Monday, 9 January 2012- The natural history of renal angiomyolipomas (AML) shows increasing size and increasing risk of haemorrhage. For those patients undergoing treatment, extirpative surgery or renal angio-embolization has...

Edited by: JV

New targeted therapy drug shows longer PFS in kidney cancer

Thursday, 5 January 2012- Patients with advanced renal cell carcinoma had modestly longer progression-free survival when treated with tivozanib, an investigational targeted therapy, than with sorafenib (Nexavar) in a head-to-head...

Edited by: JV

Kidney cancer subtypes distinguished, promising new drug targets suggested

Monday, 2 January 2012- Recent studies by Van Andel Research Institute scientists are providing a foundation for a more complete understanding of distinct kidney cancer subtypes, which could pave the way for better treatments....

Edited by: JV

Increasing US kidney cancer incidence differs by age

Wednesday, 21 December 2011- The increase in renal cancer incidence seen from 1995 to 2006 in the United States differs by age, according to a study published in the January issue of the Journal of Urology.

Dr. Kenneth G....

Edited by: JV

FDA advisory panel okays renal cell carcinoma drug

Friday, 9 December 2011- The FDA's Oncologic Drugs Advisory Committee voted 13-0 that the FDA should approve the vascular endothelial growth factor receptor inhibitor axitinib (Inlyta) for patients with advanced renal cell...

Edited by: JV

Frequent mutation of genes encoding Ubiquitin-Mediated Proteolysis Pathway components in kidney cancer

Tuesday, 6 December 2011- A study in China revealed that alteration of the ubiquitin-mediated proteolysis pathway (UMPP) may contribute to clear cell renal cell carcinoma (ccRCC ) by activation of the hypoxia regulatory network,...

Edited by: JV

Sunitinib therapy linked with hyperparathyroidism

Tuesday, 29 November 2011- Almost 70% of patients taking sunitinib (Sutent) as first-line therapy for metastatic renal cell carcinoma developed hyperparathyroidism, Italian researchers report.

The clinical significance is...

Edited by: JV

Novel role identified for PEA-15 protein in kidney cancer growth

Friday, 25 November 2011- A new study from the University of Hawaii Cancer Center reveals that PEA-15, a protein previously shown to slow ovarian tumor growth and metastasis, can alternatively enhance tumor formation in kidney...

Edited by: JV

Contemporary trends in nephrectomy for kidney cancer in the US

Thursday, 24 November 2011- Despite benefits in functional renal outcome and the similar oncological efficacy of partial nephrectomy for renal cell carcinoma, previous studies show marked underuse of partial nephrectomy. We...

Edited by: JV

Oncological result of contemporary radical nephrectomy in kidney cancer patients

Thursday, 17 November 2011- H. Miyake and colleagues conducted a study which retrospectively compared cancer control in patients with pT1 renal cell carcinoma (RCC) undergoing either open radical nephrectomy (ORN) or laparoscopic...

Edited by: JV

Kidney cancer: every minute counts

Wednesday, 16 November 2011- The 3rd European Multidisciplinary Meeting on Urological Cancers (EMUC) raised a vast array of controversial issues in onco-urology and offered essential updates, providing common ground for building...

By Evgenia Starkova

Node-positive kidney cancer in the absence of distant metastases: predicting cancer-specific mortality

Monday, 14 November 2011- Nodal metastases, even in the absence of distant metastases, portend a bad prognosis. The percentage of positive nodes (PPN) represents an important predictor of cancer-specific mortality (CSM) in...

Edited by: JV

eXTReMe Tracker